...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis
【24h】

Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis

机译:原发性胆管炎循环死亡肝移植循环死亡肝移植后的临床结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Graphical abstract Display Omitted Highlights ? Outcomes of DCD vs. DBD liver transplantation in PSC are compared. ? Operation times, need for intensive care support, and incidence of renal injury were not increased. ? DCD transplantation in PSC did not increase risk of non-anastomotic biliary strictures overall. ? Incidence of ischaemic-type biliary lesions is heightened in the first year for DCD recipients. ? Overall risk of hepatic artery thrombosis is greatest in patients with inflammatory bowel disease. ? Graft survival is not significantly different for PSC patients receiving a DCD vs. DBD liver. Background & Aim Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy for which liver transplantation is the only life-extending intervention. These patients may benefit from accepting liver donation after circulatory death (DCD), however their subsequent outcome is unknown. The aim of this study was to determine the clinical impact of using DCD liver grafts in patients specifically undergoing transplantation for PSC. Methods Clinical outcomes were prospectively evaluated in PSC patients undergoing transplantation from 2006 to 2016 stratified by donor type (DCD, n=35 vs. donation after brainstem death [DBD], n=108). Results In liver transplantation for PSC; operating time, days requiring critical care support, total ventilator days, incidence of acute kidney injury, need for renal replacement therapy (RRT) or total days requiring RRT were not significantly different between DCD vs. DBD recipients. Although the incidence of ischaemic-type biliary lesions was greater in the DCD group (incidence rate [IR]: 4.4 vs. 0 cases/100-patient-years; p p =0.624), or in sub-analysis specific to anastomotic strictures or recurrent PSC, between donor types. Graft loss and mortality rates were not significantly different following transplantation with DCD vs. DBD livers (IR: 3.6 vs. 3.1 cases/100-patient-years, p =0.34; and 3.9 vs. 4.7, p =0.6; respectively). DCD liver transplantation in PSC did not impart a heightened risk of graft loss (HR: 1.69, 0.58–4.95, p =0.341) or patient mortality (0.75, 0.25–2.21, p =0.598). Conclusion Transplantation with DCD ( vs. DBD) livers in PSC patients does not impact graft loss or patient survival. In an era of organ shortage, DCD grafts represent a viable therapeutic option for liver transplantation in PSC patients. Lay summary: This study examines the impact of liver transplantation in primary sclerosing cholangitis (PSC) with organs donated after circulatory death (DCD), compared to donation after brainstem death (DBD). We show that in appropriately selected patients, the outcomes for DCD transplantation mirror those using DBD livers, with no significant differences in complication rate, patient survival or transplanted liver survival. In an era of organ shortage and increasing wait-list times, DCD livers represent a potential treatment option for transplantation in PSC.
机译:图形抽象显示省略了亮点?比较PSC中DCD与DBD肝移植的结果。还操作时间,需要强化护理支持,肾损伤的发病率没有增加。还PSC中的DCD移植在整体上没有增加非吻合胆道狭窄的风险。还DCD接受者的第一年提高了缺血式胆道病变的发病率。还肝动脉血栓形成的总体风险最大,炎症性肠病患者最大。还PSC患者接受DCD与DBD肝脏的PSC患者没有显着差异。背景和目标原发性硬化性胆管炎(PSC)是一种渐进式炎症性胆管疗病,肝移植是唯一的生命延伸干预。这些患者可能受益于接受循环死亡(DCD)后接受肝脏捐赠,但其后续结果未知。本研究的目的是确定使用DCD肝移植物在特异性接受PSC移植患者中的临床影响。方法对经历2006至2016年移植的PSC患者预期评估临床结果(DCD,N = 35对脑干死亡后捐赠[DBD],n = 108)。结果PSC肝移植;经营时间,需要关键护理支持的天数,呼吸天数,急性肾损伤的发病率,需要肾脏替代疗法(RRT)或需要RRT的总日在DCD与DBD受体之间没有显着差异。虽然DCD组中缺血性胆量病变的发生率大于(发病率[IR]:4.4与0例/ 100患者 - 年; PP = 0.624),或者在特定于吻合狭窄或复发的子分析中PSC,供体类型之间。随着DCD与DBD肝脏移植后移植损失和死亡率没有显着不同(IR:3.6对3.1例/ 100患者 - 年,P = 0.34;和3.9与4.7,P = 0.6;分别)。 PSC中的DCD肝移植不赋予接枝损失的高风险(HR:1.69,0.58-4.95,P = 0.341)或患者死亡率(0.75,0.25-21,P = 0.598)。结论PSC患者中DCD(与DBD)肝脏移植不会影响移植物损失或患者存活。在器官短缺时代,DCD移植物代表PSC患者肝移植的可行治疗选择。 LAD综述:本研究审查了肺部死亡(DCD)后促进原发性胆管炎(PSC)肝移植在循环死亡(DCD)后的影响,与脑干死亡(DBD)捐赠。 We show that in appropriately selected patients, the outcomes for DCD transplantation mirror those using DBD livers, with no significant differences in complication rate, patient survival or transplanted liver survival.在器官短缺的时代和增加的等待列表时间,DCD肝脏代表PSC中移植的潜在治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号